SOMERSET, N.J., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Tuesday, March 10, 2026, to review fourth-quarter and full-year 2025 financial results. During the conference call and accompanying webcast, senior management will provide an overview of quarterly and full-year financial performance. Investors and other interested parties may access the live audio webcast via ...

Immersive Career Exploration and Skill-Building Technology Helps Formerly Incarcerated and Disconnected Students Unlock Their PotentialSAN JOSE, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- zSpace, Inc. (NASDAQ: ZSPC), a leading provider of augmented and virtual reality (AR/VR) solutions for education, today announced a partnership with Eight Million Stories, Inc., a nonprofit organization founded to disrupt the school-to-prison pipeline. Through immersive, hands-on learning, zSpace technology is helping forme ...

EDGEWOOD, N.Y., Feb. 24, 2026 (GLOBE NEWSWIRE) -- CPI Aerostructures, Inc. (“CPI Aero” or the “Company”) (NYSE American: CVU) announced that Lockheed Martin Aeronautics has placed several additional orders totaling $9 million against a previously announced Long Term Agreement to manufacture the Rudder Island Drag Chute Canister (RI/DCC) assemblies for the F-16 Block 70/72 fighter jets. These new orders will see deliveries continue through 2028. CPI Aero delivered its first RI/DCC assembly for the F-16 Block ...

NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies for cancer and autoimmune diseases, today announced that William Ho, CEO and co-founder, will be presenting at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, at 9:50 am ET. William Ho will be giving a company presentation highlighting IN8bio’s latest achievements and upcoming milestones. The conference, to be held Mar ...

PITTSBURGH, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Axe Compute, Inc. (NASDAQ: AGPU) today announced that it has engaged Cardiff Advisory LLC, a leading investment bank specializing in life sciences and strategic advisory services, to assist the Company in exploring strategic alternatives for its Helomics Business. The strategic review process will be conducted under the oversight of the Company’s Board of Directors and may include a sale, partnership, licensing arrangement, joint venture, or other transaction in ...

MADRID and CAMBRIDGE, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, Ticker: ORY), a clinical-stage biopharmaceutical company and a global leader in epigenetics, today announced that the European Medicines Agency (EMA) has authorized its Clinical Trial Application (CTA) to initiate a Phase II study of iadademstat, Oryzon’s potent and selective LSD1 inhibitor currently in clinical development in oncology and hematology, for the treatment of essential thrombocythemia ...

JERSEY CITY, N.J., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Moomoo, a leading global investment and trading platform, today named Queens Gateway to Health Sciences Secondary School the winning school in the Student Stock Showdown challenge, a 13-week paper trading competition delivered in partnership with Working in Support of Education (W!se), an educational nonprofit based in New York City. The recognition honors Queens Gateway’s strong overall performance and student engagement throughout the program, which bro ...

MOUNTAINHOME, Pa., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Tianrong Internet Products and Services Inc. (OTC: TIPS) (“TIPS” or the “Company”), a Pennsylvania-based technology company focused on blockchain incubation and decentralized infrastructure initiatives, today provided an operational update following the February 17, 2026 launch of the DEPIN token for the Depinfer project on the Solana blockchain via Raydium. As previously announced on February 18, 2026, the DEPIN token successfully graduated from incubati ...

Tel Aviv, Israel, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Viewbix Inc. (Nasdaq: VBIX) (“Viewbix” or the “Company”), an advanced technologies company, announced today that Quantum Transportation Ltd. ("Quantum Transportation" or "QT"),- a minority-owned subsidiary of Quantum X Labs Ltd., the Israeli quantum tech group Viewbix is in the process of acquiring, has successfully achieved a key cloud implementation milestone in its transformer-based quantum decoder program. Following the successful initial validation of ...

Core Viewpoint - Helus Pharma has appointed Dr. Freda Lewis-Hall to its Board of Directors and as Chair of the Scientific Advisory Committee, aiming to enhance its clinical development strategy and regulatory engagement for its novel serotonergic agonist portfolio [2][6]. Company Overview - Helus Pharma is a clinical stage pharmaceutical company focused on developing novel serotonergic agonists (NSAs) to address serious mental health conditions such as depression and anxiety [9][10]. - The company operates in Canada, the United States, the United Kingdom, and Ireland [11]. Leadership Appointment - Dr. Freda Lewis-Hall brings over 40 years of experience in clinical care, research, and corporate leadership, having previously served as Executive Vice President and Chief Medical Officer at Pfizer [3][4]. - Her role will involve providing leadership in scientific, clinical, and regulatory governance across Helus' portfolio, advising on discovery opportunities and clinical development strategies [6][7]. Clinical Development Focus - Helus Pharma is currently developing HLP003, a proprietary NSA in Phase 3 clinical development for major depressive disorder, which has received Breakthrough Therapy Designation from the U.S. FDA [10]. - HLP004, another proprietary NSA, is in Phase 2 for generalized anxiety disorder [10]. Strategic Goals - The company aims to improve the treatment landscape for mental health through its innovative NSAs, focusing on delivering meaningful outcomes for patients and long-term value for stakeholders [6][10].